Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADB-101
- Development stage
- Preclinical
- Lead developer
- Adolore Biotherapeutics
- Modality
- Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
- Administration
- Local Injection
01
Overview
ADB-101 is a preclinical gene therapy program being developed by Adolore Biotherapeutics for the treatment of erythromelalgia, a rare and severe form of neuropathic pain. The therapy utilizes the proprietary ADLR-1001 platform, which employs a non-toxic, replication-deficient herpes simplex virus (rdHSV) vector (JDNI8) to deliver a variant of the carbonic anhydrase-8 (CA8*) analgesic peptide. ADB-101 is designed for localized delivery to the peripheral somatosensory nervous system, where the expressed CA8* peptide acts as a neuromodulator by activating Kv7 voltage-gated potassium channels. This activation decreases the excitability of pain-sensing neurons, thereby reducing pain signaling. The program is currently in IND-enabling studies and aims to provide a long-term, disease-free treatment option for genetically determined chronic pain.
- Other names
- JDNI8 rdHSV-CA8*
02
Targets
KCNQ (Potassium voltage-gated channel subfamily Q (Kv7))
Beyond the preview
Go deeper on ADB-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADB-101.